type,message,urgency,timestamp,period,decision_context
monitoring,The FDA is aware of an emerging drug shortage situation. We are actively monitoring the supply and are encouraging manufacturers to report any disruptions. Stakeholders are advised to maintain regular communication to minimize impact.,elevated,2025-07-30T14:35:36.643138,1,"{'shortage_assessment': 'The shortage is emerging with one known manufacturer disruption. Supply is insufficient but the situation is not critical yet.', 'intervention_justification': 'A monitoring statement is appropriate to promote transparency and industry coordination without causing undue panic or market destabilization.', 'market_impact_prediction': 'Manufacturers may increase their production capacity voluntarily. Limited buyer stockpiling may occur but is not expected to significantly worsen the situation.', 'patient_safety_considerations': 'Current patient safety risks are low to moderate, and there is no immediate danger to patient access that justifies a critical shortage announcement.'}"
